Obesity Services & Products
-
Collect RWE With Natural History Studies
9/20/2023
Developing a therapy for a rare or ultra-rare disease is life-changing work with unique challenges. Examine how natural history data is being used to inform the clinical development process.
-
Get Phase-Appropriate CMC Support
9/20/2023
Strategic product development and CMC regulatory planning start early on at the pre-IND stage and apply to the entire development lifecycle through to post-approval.
-
Get It Right The First Time: Strategic Clinical Development
9/20/2023
Start early and get it right the first time. Course correct with a changing landscape. Overcome obstacles within clinical development. Collaborate with the best strategists and problem-solvers in clinical development.
-
Efficiency, Flexibility, And Speed: Building Better Clinical Trials
9/19/2023
Zelta’s EDC has been used in more than 4,000 studies from startup to submission, across all phases, including over 500 phase 3c trials and 23 therapeutic areas.
-
Orphan And Rare Disease CRO Services
6/27/2023
There may be as many as 8,000 rare diseases, affecting between 6% and 8% of the worldwide population in total. It is estimated there are about 30 million affected people in the EU and in North America, while over 45 million people may be suffering from a rare condition in Asia, with 10 million people in China alone.
-
Infectious Diseases And Vaccines CRO Services
6/27/2023
Many biotechnology companies look at the Asia-Pacific region for their trials in Infectious diseases and Vaccines due to the high prevalence of diseases such as Hepatitis (Hepatitis B, Hepatitis C), HIV, and Influenza across the region.
-
Liver Disease CRO Services
6/27/2023
Biotechnology companies consider locations in the Asia-Pacific region, such as South Korea and China to access vast treatment-naïve patient populations and accelerate their clinical trials at lower costs.
-
GMO Solutions
6/27/2023
Novotech initiated the first national, privately owned, commercial Institutional Biosafety Committee (IBC) in Australia, successfully accredited by the Australian Office of the Gene Technology Regulator (OGTR).
-
Pharmacometric Services
6/27/2023
Our talented and experienced team can assist in all Clinical Study Phases (Phase 0, I, II and III) and in study designs ranging from First in Human (FIH), Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Drug-Drug Interaction (DDI), Bioavailability/Bioequivalence (BA/BE), Food Effect as well as Special Population studies.
-
Oncology CRO Services
6/27/2023
Biotechnology companies are facing increased challenges around participant recruitment and retention, lengthy timeframes, and relatively high costs.